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Appendix 1. Acronyms or abbreviations for studies included in the current report 
and their key references linked to the Web references 
1. General population cohorts
Aichi:  Aichi Workers’ Cohort
1
ARIC:  Atherosclerosis Risk in Communities Study
2
AusDiab:  Australian Diabetes, Obesity, and Lifestyle Study
3
Beaver Dam: Beaver Dam CKD Study
4
Beijing:  Beijing Cohort Study
5
CHS:   Cardiovascular Health Study
6
CIRCS: Circulatory Risk in Communities Study
7
COBRA:  COBRA Study
8
ESTHER:  ESTHER Study
9
Framingham: Framingham Heart Study
10
Gubbio:  Gubbio Study
11
HUNT:  Nord Trøndelag Health Study
12
IPHS:   Ibaraki Prefectural Health Study
13
MESA:  Multi-Ethnic Study of Atherosclerosis
14
MRC Older People: MRC Study of assessment of older people
15
NHANES III: Third US National Health and Nutrition Examination Survey
16
Ohasama:  Ohasama Study
17
Okinawa83: Okinawa 83 Cohort
18
Okinawa93: Okinawa 93 Cohort
19
PREVEND: Prevention of Renal and Vascular End-stage Disease Study
20
Rancho Bernardo: Rancho Bernardo Study
21
REGARDS:   Reasons for Geographic And Racial Differences in Stroke Study
22
Severance:  Severance Cohort Study
23
Taiwan:  Taiwan MJ Cohort Study
24
ULSAM:  Uppsala Longitudinal Study of Adult Men
25
2. High-risk cohorts
ADVANCE: The Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) trial
26
CARE: The Cholesterol and Recurrent Events (CARE) Trial
27
KEEP: Kidney Early Evaluation Program
28
KPHawaii: Kaiser Permanente Hawaii Cohort
29
MRFIT: Multiple Risk Factor Intervention Trial
30
Pima: Pima Indian Study
31
ZODIAC: Zwolle Outpatient Diabetes project Integrating Available Care
32
3. CKD cohorts
AASK:  African American Study of Kidney Disease and Hypertension
33
BC CKD British Columbia CKD Study
34
CRIB:   Chronic Renal Impairment in Birmingham
35
Geisinger: Geisinger CKD Study
36
GLOMMS-1: GLOMMS-1: Grampian Laboratory Outcomes, Morbidity and Mortality 
Studies – 1
37
KPNW: Kaiser Permanente Northwest
38
MASTERPLAN: Multifactorial Approach and Superior Treatment Efficacy in Renal 
Patients with the Aid of a Nurse Practitioner
39
MDRD:  Modification of Diet in Renal Disease Study
40
MMKD: Mild to Moderate Kidney Disease Study
41
Nephro Test: NephroTest Study
42
RENAAL:  Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with 
the Angiotensin II Antagonist Losartan
43
Steno:   Steno Type 1 Diabetes Study
44
Sunnybrook: Sunnybrook Cohort
45
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Appendix 2. Data analysis overview and analytic notes for some of individual studies 
Overview: 
The participating studies were asked to prepare a dataset with approximately 30 variables 
(follow-up time, event variable, and several predictors including age, gender, race and serum 
creatinine to estimate GFR and albuminuria). To minimize heterogeneity, we circulated 
guidelines for definitions of variables (e.g. hypertension, diabetes, smoking) and dataset 
preparation. Analyses were restricted to subjects aged 18 years or older. We instructed studies 
not to impute the two key kidney measures, eGFR (i.e., age, gender, race, and serum creatinine) 
and albuminuria.  For other variables in the models with missing values we imputed with the 
mean value of the covariate. Individuals with practically impossible values of covariates, i.e., 
systolic blood pressure <50 or >300 mmHg or BMI <10 or >100 kg/m
2
 were excluded from the
analysis (<0.01 %).  
For 35 of the 45 studies analysis was done at the Data Coordination Center at Johns Hopkins 
University; for the remainder the standard code was run in-house at individual study centers, 
with the output returned to the Data Coordinating Center. The code was written in STATA by 
the Data Coordinating Center. The standard code was designed to automatically save all output 
needed for the meta-analysis. The Data Coordinating Center then pooled the estimates across 
studies using STATA.   
Studies were instructed to standardize and calibrate their serum creatinine to their best ability and 
report the method of standardization.  The reported creatinine calibration allows grouping studies 
into studies that reported using an IDMS traceable method or conducted some serum creatinine 
calibration to IDMS traceable methods (AusDiab, Beaver Dam, Geisinger, GLOMMS-1, 
Gubbio, HUNT, KEEP, KPNW, MMKD, NephroTest, NHANES III, Okinawa 83 and 93, 
Rancho Bernardo, REGARDS) and studies where the creatinine standardization was not done 
(AASK, ADVANCE, Aichi, ARIC, British Columbia CKD, Beijing, CARE, CHS, CIRCS, 
COBRA, CRIB, ESTHER, Framingham, IPHS, KP Hawaii, MASTERPLAN, MDRD, MESA, 
MRC Older People, MRFIT, Ohasama, Pima, PREVEND, RENAAL, Severance, STENO, 
Sunnybrook, Taiwan, ULSAM, ZODIAC).  Retrospective assessment of creatinine calibration 
without direct collection of laboratory data is limited since substantial creatinine calibration 
differences have been documented even within a single laboratory using the same method over 
time.  
The reference range of eGFR (90-104 ml/min/1.73 m
2
) was chosen based on the optimal level of
GFR (≥90 ml/min/1.73 m
2
) reported in current clinical guidelines
46, 47
 and the fact that some
studies have reported higher mortality risk at high eGFR.
48-50
 The reference point of eGFR (95
ml/min/1.73 m
2
) was then arbitrarily chosen within the reference range but not in the knots (90
and 105) used to create splines.   
Following the published results from individual studies, we assumed the proportional hazards 
model provided the best summary of the data in each study and did not summarize statistics on 
deviations from proportionality across the covariates.   
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Notes for individual studies: 
1. General population cohorts
CHS: This study consists of participants only aged 65 or older and thus did not contribute to the 
subgroup analysis of younger population.  
COBRA: Current smokers in this study include chewable tobacco users. 
ESTHER: This study only measured urine albumin excretion with the minimum detection value 
of 11.3 mg/L (equivalent to ACR 17 mg/g) and thus its reference proteinuria group (≤11.3 mg/L) 
was likely to contain individuals with ACR ≥10 mg/g. Therefore, this study was meta-analyzed 
with the dipstick studies, translating urine albumin excretion (≤11.3, 11.4-19.9, 20-199 and ≥200 
mg/L to -, ±, +, and ≥++). 
Gubbio: This study consists of participants aged between 45 and 64 and thus did not contribute 
to the subgroup analysis of older population. 
HUNT: This study is a general-population study overall but measured urine albumin mainly in 
participants with treated hypertension or diabetes. However, this study was categorized as a 
general population cohort, since they measured albuminuria in a 5% random sample out of 
≈65,000 participants and, thus, the relationship between kidney measures and risk was 
maintained. This study has not collected use of anti-diabetic medication and use of statins (and 
thus hypercholesterolemia). Most of the glucose measurements were non-fasting.  
IPHS: This study categorized their dipstick data - and ± into the same group. Therefore, dipstick 
data - and ± were treated as a reference group, and this study did not contribute to estimates of 
dipstick ±. 
MRC Older People: This study categorized their dipstick data - and ± into the same group. 
Therefore, dipstick data - and ± were treated as a reference group, and this study did not 
contribute to estimates of dipstick ±. This study has not collected total cholesterol. This study 
consists of participants aged ≥75 years old and thus did not contribute to the subgroup analysis of 
younger population. 
NHANESIII: This study did not collect data on total cholesterol, hypercholesterolemia, or use of 
anti-diabetic medications. 
Ohasama: This study has not collected data on use of anti-diabetic medications. 
Okinawa 83: This study has not collected data on fasting glucose, smoking, history of 
cardiovascular disease, anti-diabetic or anti-hypertensive medications. 
Okinawa 93: This study has not collected data on fasting glucose, smoking, history of 
cardiovascular disease, anti-diabetic or anti-hypertensive medications. 
ULSAM: This study measured urinary albumin excretion rate (µg/min), which was converted to 
mg/day by multiplying 1.44. All participants aged 65 or older and thus this study did not 
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contribute to the subgroup analysis of younger population. This study consists of only men, thus 
did not contribute to the subgroup analysis of women. 
2. High-risk cohorts
ADVANCE: This study is an intervention study which includes participants with diabetes only. 
CARE: This study is an intervention study in which all patients had a previous myocardial 
infarction. This study did not include dipstick category “+++”. Due to many missing values, data 
for fasting glucose and BMI were not included.  
KP Hawaii: In this study for participants with only ACR, PCR was imputed by ACR * 1.5. 
MRFIT: This study is an intervention study which includes men only and thus did not contribute 
to the subgroup analysis of women. 
Pima: This study consists entirely of Pima and the closely-related Tohono O’odham Indians. 
ACR was measured in a spot urine specimen. History of cardiovascular disease was not recorded 
in this study.  
ZODIAC: This study includes only individuals with type 2 diabetes. This study has not collected 
data on fasting glucose or hypercholesterolemia. 
3. CKD cohorts
AASK: This study is an intervention study which includes African American participants only. 
All participants were free of diabetes. 
Geisinger: This study includes all Geisinger primary care recipients, 18 years or older as of index 
date, and who have CKD, defined as two or more outpatient eGFR values < 60 by CKD-EPI 
equation. Covariates obtained most closely to index date within a past year were included in 
models. 
GLOMMS-1: This study did not collect data on use of anti-diabetic or anti-hypertensive 
medication, total cholesterol, systolic or diastolic blood pressure, or BMI. Diabetes and 
hypertension status were coded based on hospital physician or general practitioner diagnosis 
recorded in case notes. The ethnicity of the Grampian population is relatively homogenous with 
overall 98.3% of males and 98.4% of females being white. Indians account for 0.2% of the 
population, Pakistani and other South Asian individuals account for 0.3%, Chinese 0.3% and 
0.8% are recorded as other.
51
KPNW: This study defined diabetes using their own clinical tool that includes diagnosis codes, 
treatment codes, and laboratory values. This study has not collected use of anti-diabetic 
medications. 
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MASTERPLAN: This study measured ACR in patients with albuminuria in the low range, PCR 
in patients with overt proteinuria. Thus, for those participants with only ACR, PCR was imputed 
by ACR * 1.5. 
MDRD: This study has not collected use of anti-diabetic or anti-hypertensive medications, use of 
statins, or hypercholesterolemia. 
MMKD: This study measured 24h proteinuria. 
RENAAL: This was a randomized controlled trial to determine whether the angiotensin receptor 
blocker losartan confers renoprotection in patients with type 2 diabetes and nephropathy. 
Steno: Although this study has recruited type 1 diabetes mellitus patients with and without 
diabetic nephropathy, only participants with ACR ≥ 30 mg/g at baseline were included in this 
study as a CKD cohort. All participants had hypercholesterolemia. 
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Appendix 3. Acknowledgements and funding for collaborating cohorts 
Study List of sponsors 
AASK NIDDK 
ADVANCE National Health and Medical Research Council of Australia program grant 
571281; Servier 
Aichi KAKENHI (09470112, 13470087, 17390185, 18590594, 20590641, 
20790438, 22390133) 
ARIC The Atherosclerosis Risk in Communities Study is carried out as a 
collaborative study supported by National Heart, Lung, and Blood Institute 
contracts (HHSN268201100005C, HHSN268201100006C, 
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, 
HHSN268201100010C, HHSN268201100011C, and 
HHSN268201100012C). The authors thank the staff and participants of the 
ARIC study for their important contributions. 
AusDiab The Baker IDI Heart and Diabetes Institute, Melbourne, Australia, their 
sponsors, and the National Health and Medical Research Council of 
Australia (NHMRC grant 233200), Amgen Australia, Kidney Health 
Australia and The Royal Prince Alfred Hospital, Sydney, Australia. 
BC Cohort BC Provincial Renal Agency, an Agency of the Provincial Health Services 
Authority in collaboration with University of British Columbia. 
Beaver Dam NIH/NIDDK DK73217 
NIH/NEI  EY 006594 
Beijing The research for this study was supported by the Program for New Century 
Excellent Talents in University (BMU2009131) from the Ministry of 
Education of the People’s Republic of China, and the grants for the Early 
Detection and Prevention of Non-communicable Chronic Diseases from the 
International Society of Nephrology Research Committee. 
CARE Alberta Heritage Foundation for Medical Research/Alberta Innovates Health 
Solutions Interdisciplinary Team Grants Program 
CHS The research reported in this article was supported by contracts 
HHSN268201200036C, N01-HC-85239, N01-HC-85079 through N01-HC-
85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, 
N01-HC-45133, and grant HL080295 from the National Heart, Lung, and 
Blood Institute (NHLBI), with additional contribution from the National 
Institute of Neurological Disorders and Stroke (NINDS). Additional support 
was provided through AG-023629, AG-15928, AG-20098, and AG-027058 
from the National Institute on Aging (NIA). A full list of principal CHS 
investigators and institutions can be found at http://www.chs-
nhlbi.org/pi.htm. 
CIRCS N/A 
COBRA Wellcome Trust, UK 
CRIB British Renal Society Project Grant Award 
British Heart Foundation Project Grant Award. 
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ESTHER Ministry of Research, Science and the Arts Baden-Württemberg (Stuttgart, 
Germany), Federal Ministry of Education and Research (Berlin, Germany), 
Federal Ministry of Family Affairs, Senior Citizens, Women and Youth 
(Berlin, Germany), European Commission FP7 framework programme of 
DG-Research (CHANCES Project). Measurement of urinary albumin was 
funded by Dade-Behring, Marburg, Germany. 
Framingham NHLBI Framingham Heart Study (N01-HC-25195). 
Geisinger Geisinger Clinic 
GLOMMS-1 Chief Scientist Office CZH/4/656 
Gubbio Merck Sharp & Dohme – Italy; Municipal and Health Authorities of Gubbio, 
Italy; Center of Preventive Medicine, Gubbio, Italy; Istituto Superiore di 
Sanità, Rome, Italy; Federico II University, Naples, Italy; University of 
Milan, Milan, Italy; Northwestern University, Chicago, USA; University of 
Salerno, Italy. 
HUNT N/A 
IPHS N/A 
KEEP US National Kidney Foundation 
KP Hawaii N/A 
KPNW Amgen 
MASTERPLAN The MASTERPLAN study is a clinical trial with trial registration ISRCTN 
registry: 73187232. Sources of funding: The MASTERPLAN Study was 
supported by grants from the Dutch Kidney Foundation (Nierstichting 
Nederland, number PV 01), and the Netherlands Heart Foundation 
(Nederlandse Hartstichting, number 2003 B261). Unrestricted grants were 
provided by Amgen, Genzyme, Pfizer and Sanofi-Aventis. 
MDRD NIDDK UO1 DK35073 and K23 DK67303, K23 DK02904 
MESA This research was supported by contracts N01-HC-95159 through N01-HC-
95169 from the National Heart, Lung, and Blood Institute.  The authors 
thank the other investigators, the staff, and the participants of the MESA 
study for their valuable contributions.  A full list of participating MESA 
investigators and institutions can be found at http://www.mesa-nhlbi.org. 
MMKD The MMKD study was funded by the Austrian Heart Fund and by the 
Innsbruck Medical University. 
MRC Older 
People 
UK Medical Research Council, Department of Health for England, Wales 
and the Scottish Office and Kidney Research UK 
MRFIT The Multiple Risk Factor Intervention Trial was contracted by the National 
Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health 
(NIH), Bethesda, Md.  Follow-up after the end of the trial was supported 
with NIH/NHLBI grants R01-HL-43232 and R01-HL-68140.  The principal 
investigators and senior staff of the clinical centers, coordinating center, 
other support centers and key committees are listed in a previous report 
(JAMA 1982; 248: 1465-1477). 
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NHANES III United States Center for Disease Control 
NephroTest The NephroTest CKD cohort study is supported by grants from: Inserm GIS-
IReSP AO 8113LS TGIR; French Ministry of Health AOM 09114 and AOM 
10245; Inserm AO 8022LS; Agence de la Biomédecine R0 8156LL, AURA, 
and Roche 2009-152-447G. The Nephrotest initiative was also sponsored by 
unrestricted grants from F.Hoffman-La Roche Ltd.  
The authors thank the collaborators and the staff of the NephroTest Study: 
Gauci C, Karras A, Maruani G, Daugas E, d'Auzac C, Jacquot C, Thervet E, 
Roland M, Letavernier E, Boffa JJ, Ronco P, Fessi H, du Halgouet C, 
Vrtovsnik F, Urena P. 
Ohasama Grant-in-Aid(H20-22Junkankitou[Seishuu]-Ippan-009, 013 and H23-
Junkankitou [Senshuu]-Ippan-005) from the Ministry of Health, Labor and 
Welfare, Health and Labor Sciences Research Grants, Japan; Japan 
Atherosclerosis Prevention Fund. 
OKINAWA 83 N/A 
OKINAWA 93 N/A 
Pima This work was supported by the Intramural Research Program of the 
National Institute of Diabetes and Digestive and Kidney Diseases 
PREVEND The PREVEND study is supported by several grants from the Dutch Kidney 
Foundation, and grants from the Dutch Heart Foundation, the Dutch 
Government (NWO), the US National Institutes of Health (NIH) and the 
University Medical Center Groningen, The Netherlands (UMCG). Dade 
Behring, Marburg, Germany supplied equipment and reagents for 
nephelometric measurement of urinary albumin. 
Rancho 
Bernardo 
NIA AG07181 and AG028507 NIDDK DK31801 
REGARDS This research project is supported by a cooperative agreement U01 
NS041588 from the National Institute of Neurological Disorders and Stroke, 
National Institutes of Health, Department of Health and Human Service. The 
content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institute of Neurological 
Disorders and Stroke or the National Institutes of Health. Representatives of 
the funding agency have been involved in the review of the manuscript but 
not directly involved in the collection, management, analysis or 
interpretation of the data. The authors thank the other investigators, the staff, 
and the participants of the REGARDS study for their valuable 
contributions.  A full list of participating REGARDS investigators and 
institutions can be found at http://www.regardsstudy.org 
Additional funding was provided by an investigator-initiated grant-in-aid 
from Amgen.  Representatives from Amgen did not have any role in the 
design and conduct of the study, the collection, management, analysis, and 
interpretation of the data, or the preparation or approval of the manuscript.   
RENAAL The RENAAL trial was supported by Merck and Company. 
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Severance Seoul city R&BD program (10526), Korea, The National R&D Program for 
Cancer Control, Ministry for Health, Welfare and Family affairs, Republic 
of Korea (1220180), and The National Research Foundation of Korea(NRF) 
grant funded by the Korea government(MEST) (2011-0029348). 
STENO N/A 
Taiwan This study was supported by Taiwan Department of Health Clinical Trial 
and Research Centre of Excellence (DOH 101-TD-B-111-004) 
ULSAM The Swedish Research Council (2006-6555), the Swedish Heart-Lung 
Foundation, Dalarna University, and Uppsala University. 
ZODIAC N/A 
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Table S1. Number of events per study for Asians, whites, and blacks. 
Abbreviations: ACM, all-cause mortality; CVM, cardiovascular mortality; ESRD, end-stage renal disease; CKD, chronic kidney disease; ACR, urine albumin-to-creatinine ratio; 
PCR, urine protein-to-creatinine ratio.  *Studies with ACR, †Studies with PCR.  Within each study any racial groups with <10 events of interest were excluded. 
Study N # of case mean fu # of case mean fu # of case mean fu N # of case mean fu # of case mean fu # of case mean fu N # of case mean fu # of case mean fu # of case mean fu
Aichi 4731 50 7.4 - - - - - - - - - - - - - - - - - -
ARIC* 23 1 10.3 0 10.3 0 10.3 8874 1423 10.6 262 10.6 101 10.6 2537 497 10.5 132 10.5 88 10.4
AusDiab* - - - - - - - 11063 922 9.9 204 7.5 - - - - - - - - -
Beaver Dam 12 0 13.5 0 13.5 - - 4827 1536 11.6 688 11.6 - - 1 0 14.3 0 14.3 - -
Beijing* 1559 57 3.9 - - - - - - - - - - - - - - - - - -
CHS* 3 2 8.1 0 8.1 - - 2476 1459 8.4 552 8.4 - - 495 261 8.6 102 8.6 - -
CIRCS 11871 1597 17.0 - - - - - - - - - - - - - - - - - -
COBRA* 2872 212 4.1 95 4.1 - - - - - - - - - - - - - - - -
ESTHER - - - - - - - 9641 489 5.0 160 5.0 - - - - - - - - -
Framingham* - - - - - - - 2956 301 10.5 144 10.5 - - - - - - - - -
Gubbio* - - - - - - - 1681 117 10.7 - - - - - - - - - - -
HUNT* - - - - - - - 9659 2287 12.0 1144 12.0 91 12.0 - - - - - - -
IPHS 95451 15490 14.0 4733 14.0 - - - - - - - - - - - - - - - -
MESA* 799 31 6.2 3 6.2 - - 2598 121 6.4 29 6.4 - - 1859 107 6.1 23 6.1 - -
MRC - - - - - - - 12371 7068 6.4 2996 6.4 - - - - - - - - -
NHANES III* - - - - - - - 6381 1225 8.3 572 8.3 - - 4275 476 8.5 176 8.5 - -
Ohasama 1956 279 10.4 88 10.4 - - - - - - - - - - - - - - - -
Okinawa83 9599 - - - - 97 16.9 - - - - - - - - - - - - - -
Okinawa93 93216 - - - - 165 6.9 - - - - - - - - - - - - - -
PREVEND* 181 14 9.5 2 9.3 - - 8012 617 9.7 178 9.3 - - 84 5 9.3 2 9.1 - -
RanchoBernardo* 8 0 13.7 0 13.7 - - 1465 547 10.5 186 10.5 - - 1 1 13.2 1 13.2 - -
REGARDS* - - - - - - - 16352 1505 5.2 - - 52 5.2 10954 1138 4.9 - - 136 4.9
Severance 76201 2530 10.0 424 10.0 - - - - - - - - - - - - - - - -
Taiwan 515573 18433 8.1 3720 8.1 - - - - - - - - - - - - - - - -
ULSAM* - - - - - - - 1103 462 11.6 210 11.6 - - - - - - - - -
Overall GP 814055 38696 9.2 9065 9.1 262 7.9 99459 20079 8.4 7325 8.6 244 8.4 20206 2485 6.6 436 8.6 224 5.9
High Risk
ADVANCE* 4132 302 4.8 164 4.8 - - 6264 636 4.8 327 4.8 - - 35 2 5.0 1 5.0 - -
CARE - - - - - - - 3798 333 4.8 185 4.8 - - 132 17 4.8 12 4.8 - -
KEEP 4330 84 4.0 - - - - 35715 1406 4.1 - - - - 24571 647 4.3 - - - -
KPHawaii† - - - - - - - 39884 1590 2.4 - - 330 2.4 - - - - - - -
MRFIT 132 62 25.3 36 25.3 3 23.5 11548 6128 25.0 2865 25.0 243 23.4 930 522 24.6 230 24.6 46 23.0
Pima* - - - - - - - - - - - - - - - - - - - - -
ZODIAC* - - - - - - - 1095 455 7.9 194 7.9 - - - - - - - - -
Overall HR 8594 448 4.7 200 5.4 3 23.5 98304 10548 6.0 3571 15.2 573 7.1 25668 1188 5.0 243 21.6 46 23.0
CKD
AASK† - - - - - - - - - - - - - - 1094 254 8.8 - - 318 7.5
BC CKD* 4110 1157 3.4 - - 841 3.2 11414 3043 3.4 - - 1968 3.2 63 11 3.1 - - 24 2.8
CRIB* 20 7 6.5 3 6.5 14 3.4 270 104 6.0 54 6.0 128 4.2 18 4 6.8 1 6.8 7 4.7
GeisingerACR* 6 0 1.4 - - - - 3297 449 3.6 - - - - 52 3 3.5 - - - -
GeisingerDip 3 1 5.7 - - 1 3.4 4450 1023 3.9 - - 56 3.9 45 2 3.6 - - 1 3.5
GLOMMS-1ACR* - - - - - - - 537 314 4.2 117 4.2 - - - - - - - - -
GLOMMS-1PCR† - - - - - - - 470 261 4.2 86 4.2 85 3.7 - - - - - - -
KPNW 25 6 5.2 - - 5 4.5 1522 663 4.5 - - 94 4.4 52 14 4.9 - - 5 4.7
MASTERPLAN* 26 1 4.1 - - 5 4.1 586 66 4.1 - - 76 4.1 18 3 3.9 - - 3 3.8
MDRD† - - - - - - - 1385 605 14.0 277 14.0 883 10.1 214 92 14.0 56 14.0 130 10.5
MMKD† - - - - - - - 202 - - - - 71 4.0 - - - - - - -
NephroTest* - - - - - - - 839 - - - - 125 2.6 89 - - - - 9 2.5
RENAAL* 252 38 3.0 19 3.0 59 2.7 735 161 3.1 99 3.1 148 2.9 230 37 3.1 21 3.1 44 2.9
STENO - - - - - - - 886 175 8.8 108 8.8 75 7.8 - - - - - - -
Sunnybrook* - - - - - - - 3385 - - - - 380 2.3 - - - - - - -
Overall CKD 4442 1210 3.4 22 3.2 925 3.2 29978 6864 4.4 741 8.3 4089 3.8 1875 420 7.6 78 8.3 541 6.6
General Population
CVM ESRD
Asian White Black
ACM CVM ESRD ACM CVM ESRD ACM
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Table S2. Characteristics of individual studies by ethnicity for Hispanics and 
others. 
Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; ACR, urine albumin-to-creatinine ratio; 
PCR, urine protein-to-creatinine ratio. 
*Studies with ACR, †Studies with PCR.
‡Not included in meta-analysis due to small number of events (<10) in this racial group. 
ɑProportion of participants with ACR ≥30 mg/g or PCR ≥50 mg/g or dipstick protein ≥1+.
Study Total N % N Age 
% 
Female %DM % HTN
% Hx of 
CVD % HC
% 
Smokin
g
eGFR 
mean % Alb
% eGFR 
<60 % N Age 
% 
Female %DM % HTN
% Hx of 
CVD % HC
% 
Smokin
g
eGFR 
mean % Alb
% eGFR 
<60
General 
Population
Aichi 4731  - - - - - - - - - - -  - - - - - - - - - - -
ARIC* 11441 0.06%‡ 63 57% 0% 29% 0% 43% 14% 89 0% 0%  - - - - - - - - - - -
AusDiab* 11179  - - - - - - - - - - - 1%‡ 45 72% 17% 24% 6% 37% 27% 90 9% 3%
Beaver Dam 4857 0.2%‡ 55 40% 30% 50% 11% 50% 10% 95 10% 0% 0.1%‡ 51 14% 0% 29% 14% 29% 29% 61 0% 0%
Beijing* 1559  - - - - - - - - - - -  - - - - - - - - - - -
CHS* 2988  - - - - - - - - - - - 1% 76 43% 36% 64% 36% 43% 0% 65 29% 36%
CIRCS 11871  - - - - - - - - - - -  - - - - - - - - - - -
COBRA* 2872  - - - - - - - - - - -  - - - - - - - - - - -
ESTHER 9641  - - - - - - - - - - -  - - - - - - - - - - -
Framingham* 2956  - - - - - - - - - - -  - - - - - - - - - - -
Gubbio* 1681  - - - - - - - - - - -  - - - - - - - - - - -
HUNT* 9659  - - - - - - - - - - -  - - - - - - - - - - -
IPHS 95451  - - - - - - - - - - -  - - - - - - - - - - -
MESA* 6733 22% 61 52% 18% 42% 0% 27% 14% 84 12% 6%  - - - - - - - - - - -
MRC 12371  - - - - - - - - - - -  - - - - - - - - - - -
NHANES III* 15563 27% 41 50% 13% 21% 7% N/A 22% 107 11% 2% 4% 44 57% 10% 21% 8% N/A 21% 101 11% 4%
Ohasama 1956  - - - - - - - - - - -  - - - - - - - - - - -
Okinawa83 9599  - - - - - - - - - - -  - - - - - - - - - - -
Okinawa93 93216  - - - - - - - - - - -  - - - - - - - - - - -
PREVEND* 8385  - - - - - - - - - - - 1%‡ 43 43% 9% 24% 5% 27% 37% 93 9% 1%
Rancho Bernardo* 1474  - - - - - - - - - - -  - - - - - - - - - - -
REGARDS* 27306  - - - - - - - - - - -  - - - - - - - - - - -
Severance 76201  - - - - - - - - - - -  - - - - - - - - - - -
Taiwan 515573  - - - - - - - - - - -  - - - - - - - - - - -
ULSAM* 1103  - - - - - - - - - - -  - - - - - - - - - - -
Overall GP 940366 1% 47 51% 14% 26% 5% 27% 20% 101 12% 3% 0.1% 45 57% 11% 23% 8% 33% 272% 98 11% 4%
100% 99%
High Risk
ADVANCE* 10595  - - - - - - - - - - - 2% 64 38% 100% 80% 23% 60% 17% 74 41% 24%
CARE 4098 4% 58 12% 28% 90% 100% 75% 12% 78 18% 15%  - - - - - - - - - - -
KEEP 77902 12% 47 67% 28% 53% 9% N/A 11% 94 12% 7% 5% 51 71% 35% 60% 11% N/A 19% 88 17% 13%
KP Hawaii† 39884  - - - - - - - - - - -  - - - - - - - - - - -
MRFIT 12854 1% 46 0% 5% 62% 0% 52% 53% 90 7% 2% 0.5% 44 0% 10% 63% 0% 52% 57% 88 2% 2%
Pima* 5066  - - - - - - - - - - - 100% 33 56% 27% 18% 0% 6% 28% 120 20% 2%
ZODIAC* 1095  - - - - - - - - - - -  - - - - - - - - - - -
Overall HR 151494 6% 48 64% 28% 54% 11% 63% 12% 94 12% 7% 6% 41 62% 31% 38% 5% 8% 24% 105 19% 7%
0% 55%
CKD
AASK† 1094  - - - - - - - - - - -  - - - - - - - - - - -
BC CKD* 17426 008%‡ 54 33% 50% N/A 0% N/A 17% 27 100% 93% 10% 71 44% 21% N/A 14% N/A 4% 36 80% 87%
CRIB* 308  - - - - - - - - - - -  - - - - - - - - - - -
Geisinger ACR* 3361 0.09%‡ 83 67% 100% 100% 33% 33% 33% 58 0% 100% 0.09%‡ 56 33% 67% 100% 0% 67% 0% 52 67% 100%
Geisinger dipstick 4509 0.09%‡ 60 75% 75% 75% 50% 50% 0% 31 25% 100% 0.2%‡ 68 71% 29% 71% 29% 43% 29% 48 57% 100%
GLOMMS-1 ACR* 537  - - - - - - - - - - -  - - - - - - - - - - -
GLOMMS-1 PCR† 470  - - - - - - - - - - -  - - - - - - - - - - -
KPNW 1627  - - - - - - - - - - - 2%‡ 68 61% 43% 21% 54% 14% 0% 50 21% 82%
MASTERPLAN* 636  - - - - - - - - - - - 0.9%‡ 55 33% 50% 83% 54% 100% 17% 39 83% 83%
MDRD† 1730  - - - - - - - - - - - 8% 47 47% 10% N/A 5% N/A 10% 40 92% 79%
MMKD† 202  - - - - - - - - - - -  - - - - - - - - - - -
NephroTest* 928  - - - - - - - - - - -  - - - - - - - - - - -
RENAAL* 1513 18% 59 46% 100% 95% 21% 61% 16% 40 100% 94% 1%‡ 56 58% 100% 89% 21% 74% 11% 37 100% 95%
STENO* 886  - - - - - - - - - - -  - - - - - - - - - - -
Sunnybrook* 3385  - - - - - - - - - - -  - - - - - - - - - - -
Overall CKD 38612 1% 59 46% 97% 95% 21% 61% 16% 39 98% 86% 5% 69 45% 22% 57% 14% 46% 5% 36 80% 86%
99% 92%Percent using ACR
Percent using ACR
Percent using ACR
OtherHispanic
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Figure S1. Crude and age-standardized distribution of eGFR and albuminuria across races in general population 
cohorts. Panels A (eGFR) and B (albuminuria) show crude distribution, while panels C (eGFR) and D (albuminuria) are adjusted for age by direct standardization using US
NHANES III as a reference population. Green, black, and red bars denote the proportions of Asian, white, and black populations, respectively.
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Figure S2. Distribution of eGFR (A and C) and albuminuria (B and D) across races in high risk (A and B) and CKD (C 
and D) cohorts Panels A (eGFR) and B (albuminuria) show in high risk cohorts, while panels C (eGFR) and D (albuminuria) for CKD cohorts. Green, black, and red bars
denote the proportions of Asian, white, and black populations, respectively.
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Figure S3. Absolute risk overall of all-cause mortality (A and B), cardiovascular 
mortality (C and D), and ESRD (E and F) in general population cohorts.  
Panels A, C, and E show the unadjusted for age meta-regression analyses and panels B, D, and F show the results 
adjusted for age. 
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Figure S4. Association of ACR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in general 
population cohorts 
The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 5 mg/g. Dots represent statistically significant points. HRs were adjusted for 
age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines. 
Model does not converge for ESRD in general population with ACR (only 2 studies with multiple ethnicities and ESRD as an outcome) 
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Figure S5. Association of eGFR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in high risk 
cohorts 
The shaded area or whiskers represent 95% CIs. The reference (diamond) is eGFR 95 mL/min/1.73m
2
. Dots represent statistically significant points. HRs were 
adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and 
albuminuria.  Model does not converge for ESRD in High Risk Population (only 2 studies with multiple ethnicities and ESRD as an outcome). 
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Figure S6. Association of eGFR by ethnicity with all-cause mortality (A), cardiovascular mortality (B), and ESRD (C) in 
CKD cohorts 
The shaded area or whiskers represent 95% CIs. The reference (diamond) is eGFR 50 mL/min/1.73m
2
. Dots represent statistically significant points. HRs were 
adjusted for age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and 
albuminuria.   
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Figure S7. Association of ACR by ethnicity with all-cause mortality (A) and cardiovascular mortality (B) in high risk 
cohorts 
The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 5 mg/g. Dots represent statistically significant points.  HRs were adjusted for 
age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines.
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Figure S8. Association of ACR/PCR by ethnicity with all-cause mortality (A), cardiovascular mortality (B), and ESRD 
(C) in chronic kidney disease cohorts 
The shaded area or whiskers represent 95% CIs. The reference (diamond) is ACR 100 mg/g. Dots represent statistically significant points. HRs were adjusted for 
age, sex, smoking, systolic blood pressure, history of cardiovascular disease, diabetes, serum total cholesterol concentration, body mass index, and eGFR splines. 
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Figure S9. Forest plot across general population studies by grouping of Asian, white, 
black at eGFR 45-59 category and albuminuria 30-299 category for all-cause 
mortality 
NOTE: Weights are from random effects analysis
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Figure S10. Forest plot across general population studies by grouping of Asian, white, 
black at eGFR 45-59 category and albuminuria 30-299 category for cardiovascular 
mortality 
NOTE: Weights are from random effects analysis
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Figure S11. Forest plot across general population studies by grouping of Asian, white, 
black at eGFR 45-59 category and albuminuria 30-299 category for end-stage renal 
disease 
NOTE: Weights are from random effects analysis
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Figure S12. Relative risk of all-cause and cardiovascular mortality according to eGFR and ACR/dipstick categories in 
whites, Asian, and blacks in high risk cohorts 
Each number represents a pooled hazard ratio from meta-analysis adjusted for covariates and compared with the reference cell (REF) within each race. Bold 
numbers indicate statistical significance at P<0.05. Color shading indicates the strength of association (approximately one quarter of all cells are shaded in each 
color; Green: low; yellow: mild; orange: moderate; red: high). All hazard ratios for blacks and Asians are compared with those for whites for interaction using 
meta-regression, and stars (*) indicate a significant interaction at P<0.05. 
26 
Figure S13. Relative risk of all-cause and cardiovascular mortality according to eGFR and ACR/dipstick categories in 
whites, Asian, and blacks in chronic kidney disease cohorts 
Each number represents a pooled hazard ratio from meta-analysis adjusted for covariates and compared with the reference cell (REF) within each race. Bold 
numbers indicate statistical significance at P<0.05. Color shading indicates the strength of association (approximately one quarter of all cells are shaded in each 
color; Green: low; yellow: mild; orange: moderate; red: high). All hazard ratios for blacks and Asians are compared with those for whites for interaction using 
meta-regression, and stars (*) indicate a significant interaction at P<0.05.
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